Erasca (NASDAQ:ERAS) Stock Price Up 7.1% – Time to Buy?

Posted by George Bondi on Sep 24th, 2026

Shares of Erasca, Inc. (NASDAQ:ERAS – Get Free Report) traded up 7.1% on Thursday . The stock traded as high as $14.60 and last traded at $14.9320. Approximately 3,407,962 shares were traded during trading, a decline of 43% from the average daily volume of 5,933,491 shares. The stock had previously closed at $13.94.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Bank of America lifted their target price on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Morgan Stanley boosted their price objective on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, July 20th. HC Wainwright boosted their target price on shares of Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Jefferies Financial Group reissued a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Finally, Guggenheim increased their price target on Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.09.

Read Our Latest Research Report on ERAS

Erasca Trading Up 5.7%

The business’s fifty day moving average is $17.52 and its 200 day moving average is $15.91. The firm has a market capitalization of $5.15 billion, a P/E ratio of -15.47 and a beta of 0.64.

Erasca (NASDAQ:ERAS – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). As a group, sell-side analysts predict that Erasca, Inc. will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Erasca

Hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP acquired a new position in shares of Erasca in the 2nd quarter valued at $1,601,000. Integrated Wealth Concepts LLC purchased a new stake in Erasca during the second quarter valued at about $80,000. Squarepoint Ops LLC boosted its holdings in shares of Erasca by 42.8% in the second quarter. Squarepoint Ops LLC now owns 135,233 shares of the company’s stock worth $2,477,000 after buying an additional 40,548 shares during the period. Nykredit A S acquired a new position in shares of Erasca in the second quarter worth about $29,000. Finally, Corient Private Wealth LP purchased a new position in shares of Erasca in the second quarter worth approximately $2,150,000. 67.78% of the stock is owned by hedge funds and other institutional investors.

Erasca Company Profile

(Get Free Report)

Erasca, Inc is a clinical-stage biotechnology company focused on developing treatments for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research and development strategy is centered on precision oncology, with the goal of addressing cancers that have historically been difficult to treat because of mutations in RAS and related proteins.

Erasca’s lead investigational program is daraxonrasib, also known as RMC-6236, an oral RAS(ON) multi-selective inhibitor designed to target active RAS proteins.